{
  "@context": {
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1002/1878-0261.12564",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.tools/PriorCD",
      "@type": "sc:SoftwareApplication",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3375"
        },
        {
          "@id": "edam:topic_3379"
        },
        {
          "@id": "edam:topic_3336"
        }
      ],
      "sc:citation": [
        {
          "@id": "https://doi.org/10.1002/1878-0261.12564"
        },
        "pmcid:PMC6763777",
        "pubmed:31408580"
      ],
      "sc:description": "Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities | Prioritizing Cancer Drugs for Interested Cancer | Prioritize candidate cancer drugs for drug repositioning based on the random walk with restart algorithm in a drug-drug functional similarity network. 1) We firstly constructed a drug-drug functional similarity network by integrating pathway activity and drug activity derived from the NCI-60 cancer cell lines. 2) Secondly, we calculated drug repurposing score according to a set of approved therapeutic drugs of interested cancer based on the random walk with restart algorithm in the drug-drug functional similarity network. 3) Finally, the permutation test was used to calculate the statistical significance level for the drug repurposing score",
      "sc:featureList": [
        {
          "@id": "edam:operation_3223"
        },
        {
          "@id": "edam:operation_2436"
        }
      ],
      "sc:license": "GPL-2.0",
      "sc:name": "PriorCD",
      "sc:url": "https://cran.r-project.org/web/packages/PriorCD"
    }
  ]
}